While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...
Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Some people are making it their mission to get Novavax, rather than Pfizer or Moderna, for their COVID booster.
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
Novavax Inc. closed $10.57 below its 52-week high ($23.86), which the company reached on June 6th.
Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.
Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option. Jessica is a writer on the Wellness team with a focus on health technology ...
Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organization Dr ...